CO2023006912A2 - Nuevos derivados de indazol acetileno - Google Patents

Nuevos derivados de indazol acetileno

Info

Publication number
CO2023006912A2
CO2023006912A2 CONC2023/0006912A CO2023006912A CO2023006912A2 CO 2023006912 A2 CO2023006912 A2 CO 2023006912A2 CO 2023006912 A CO2023006912 A CO 2023006912A CO 2023006912 A2 CO2023006912 A2 CO 2023006912A2
Authority
CO
Colombia
Prior art keywords
indazole
acetylene
new derivatives
formula
derivatives
Prior art date
Application number
CONC2023/0006912A
Other languages
English (en)
Spanish (es)
Inventor
Georg Jaeschke
Antonio Ricci
Annick Goergler
Sander Ulrike Obst
Cosimo Dolente
David Stephen Hewings
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2023006912A2 publication Critical patent/CO2023006912A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2023/0006912A 2020-12-01 2023-05-26 Nuevos derivados de indazol acetileno CO2023006912A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01
PCT/EP2021/083279 WO2022117477A1 (en) 2020-12-01 2021-11-29 New indazole acetylene derivatives

Publications (1)

Publication Number Publication Date
CO2023006912A2 true CO2023006912A2 (es) 2023-06-09

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0006912A CO2023006912A2 (es) 2020-12-01 2023-05-26 Nuevos derivados de indazol acetileno

Country Status (15)

Country Link
US (1) US20240002390A1 (https=)
EP (1) EP4255908A1 (https=)
JP (1) JP7840327B2 (https=)
KR (1) KR20230116799A (https=)
CN (1) CN116490182A (https=)
AR (1) AR124170A1 (https=)
AU (1) AU2021393722A1 (https=)
CA (1) CA3197659A1 (https=)
CL (1) CL2023001440A1 (https=)
CO (1) CO2023006912A2 (https=)
CR (1) CR20230218A (https=)
IL (1) IL303064A (https=)
MX (1) MX2023006176A (https=)
PE (1) PE20240099A1 (https=)
WO (1) WO2022117477A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114008049B (zh) 2019-06-21 2024-07-05 豪夫迈·罗氏有限公司 用于癌症治疗的egfr抑制剂
JP7840324B2 (ja) 2020-12-01 2026-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
JP2025516543A (ja) * 2022-05-13 2025-05-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
SG11202011818YA (en) * 2018-06-29 2020-12-30 Hoffmann La Roche Compounds
CN113993591A (zh) * 2019-06-21 2022-01-28 豪夫迈·罗氏有限公司 新egfr抑制剂

Also Published As

Publication number Publication date
CN116490182A (zh) 2023-07-25
US20240002390A1 (en) 2024-01-04
JP7840327B2 (ja) 2026-04-03
PE20240099A1 (es) 2024-01-18
CR20230218A (es) 2023-07-07
CA3197659A1 (en) 2022-06-09
EP4255908A1 (en) 2023-10-11
JP2023550902A (ja) 2023-12-06
WO2022117477A1 (en) 2022-06-09
TW202237611A (zh) 2022-10-01
AR124170A1 (es) 2023-02-22
CL2023001440A1 (es) 2023-12-01
MX2023006176A (es) 2023-06-08
AU2021393722A1 (en) 2023-04-13
KR20230116799A (ko) 2023-08-04
IL303064A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CO2023006912A2 (es) Nuevos derivados de indazol acetileno
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
PE20231938A1 (es) Inhibidores de cdk y metodos de uso de estos
MX2025004220A (es) Compuestos triciclicos y sus usos
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
PY2146661A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
AR121226A1 (es) Compuestos y usos de estos
PE20211810A1 (es) Compuestos novedosos
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR066972A1 (es) Derivados azapeptidicos
CL2024001481A1 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
PY2167570A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2023012958A (es) Compuestos y metodos anticonceptivos.
CR20240216A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CL2023002908A1 (es) Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3
CL2023003168A1 (es) Moduladores de trex1
AR125963A1 (es) Inhibidores de alk2 quinasa que contienen imidazol
MX2024008745A (es) Compuesto derivado de 1,3-benzodioxol y composicion farmaceutica que comprende el mismo.